Mabylon AG Revenue and Competitors
Estimated Revenue & Valuation
- Mabylon AG's estimated annual revenue is currently $3.7M per year.
- Mabylon AG's estimated revenue per employee is $155,000
- Mabylon AG's total funding is $21M.
Employee Data
- Mabylon AG has 24 Employees.
- Mabylon AG grew their employee count by -8% last year.
Mabylon AG's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
Mabylon AG Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $99.4M | 458 | 40% | N/A | N/A |
#2 | $20.6M | 133 | 22% | N/A | N/A |
#3 | $156.1M | 146 | -70% | $145M | N/A |
#4 | $3.5M | 45 | -25% | $150M | N/A |
#5 | $1.6M | 21 | 0% | $459.5M | N/A |
#6 | $67.3M | 310 | 16% | $180.7M | N/A |
#7 | $8.5M | 55 | -2% | N/A | N/A |
#8 | $256.3M | 1025 | 9% | $168.5M | N/A |
#9 | $2.8M | 18 | -33% | N/A | N/A |
#10 | $9.1M | 59 | -9% | N/A | N/A |
What Is Mabylon AG?
Mabylon AG, a private Swiss biotech company, is leading innovation in antibody-based treatments for severe allergies, inflammation, and neurological disorders. Our B-cell screening platform identifies natural human antibodies with high specificity and therapeutic potential. MY006, our first-in-class multispecific antibody therapeutic for peanut allergy, is tackling the growing food allergy market.
keywords:N/A
$21M
Total Funding
24
Number of Employees
$3.7M
Revenue (est)
-8%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $2.4M | 24 | N/A | N/A |
#2 | $5.1M | 24 | N/A | N/A |
#3 | $2.4M | 24 | N/A | N/A |
#4 | $2.2M | 24 | N/A | N/A |
#5 | $2.4M | 24 | N/A | N/A |